US 8951969

I'll verify against live sources before summarizing.

Let me run targeted searches on this specific patent's litigation/PTAB history and any 2026 CAFC activity.

Let me check specifically for CAFC/2026 docket activity and any reexamination involving this exact patent.

US 8,951,969 B2 — Verification Summary

Search scope note: I treated "8951969" literally and searched for that exact number. I did not auto-correct it to related family members. Where I could not confirm something with authoritative sources, I say so explicitly rather than inferring.

Bibliographic data (confirmed against the patent text and independent sources)

Inventorship flag: the recordation of the 2015‑02‑04 assignment lists a "BONADEO, DANIELE" but also "BRAGLIA, RICCARDO" among assignors, while Riccardo Braglia is not a named inventor on the face of the patent. I cannot resolve this from available sources; treat the five named inventors above as authoritative for the face of the patent.

Abstract (verbatim)

"Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery."

Note that the abstract is materially narrower in appearance than the specification, which is largely directed to netupitant NK₁‑receptor occupancy/durability, palonosetron–netupitant pharmacokinetic interaction, and a dexamethasone‑sparing combination regimen.

Plain‑language overview of each independent claim

Claim 1 — Fixed‑dose oral composition. An oral dosage form containing about 0.56 mg palonosetron hydrochloride and about 300 mg netupitant as the free base. In plain terms: the commercial capsule dose (0.56 mg of the HCl salt corresponds to 0.50 mg free base) with netupitant.

Claim 2 — Capsule architecture. An oral capsule with a hard outer shell that physically houses (a) three tablets, each containing about 100 mg netupitant, and (b) one soft‑gel capsule containing about 0.56 mg palonosetron HCl. This claim is directed to the physical separation of the two actives inside a single hard shell (the design rationale given in the specification is avoiding palonosetron degradation, e.g., to the (3S)‑3‑[(3aS)‑1‑oxo‑…]‑1‑azoniabicyclo[2.2.2]octan‑1‑olate by‑product). Dependent claims 3–6 add: the 0.56 mg/300 mg dose (3); ≤3 wt.% of the palonosetron degradation by‑product (4); outer‑shell oxygen permeability <1.0×10⁻³ ml·cm/(cm²·24 hr·atm) (5); and a soft‑gel fill with about 75–98 wt.% lipophilic components (6).

Claim 7 — PK‑defined oral dosage form (tmax). An oral dosage form containing therapeutically effective amounts of netupitant and palonosetron, defined by a result‑to‑result comparison rather than by amounts: a single dose must give a median netupitant tmax about 0.5 hours shorter than the same amount of netupitant given alone.

Claim 8 — PK‑defined oral composition (AUC). An oral pharmaceutical composition of netupitant and palonosetron where a single dose gives a greater netupitant AUC than the same amount of netupitant alone. Dependent claims 9–11 add greater netupitant Cmax (9), shorter netupitant tmax (10), and specifically a 0.5‑hour shorter median tmax (11).

Analytical caveats you should be aware of

1. Claims 7–11 vs. the specification's own data. The specification's Example 2 reports the improved pharmacokinetics in terms of palonosetron, not netupitant: Table 4 shows palonosetron AUC₀‑t 67,415 → 74,230 h·µg/L, Cmax 1,638.4 → 1,863.1 µg/L, and median tmax 5.02 → 4.50 h (a 0.5‑hour shortening) when netupitant is co‑administered. By contrast, Table 3 shows netupitant essentially unchanged: AUC₀‑t 22,808 → 22,775 h·µg/L, Cmax 650.2 → 659.7 µg/L, and median tmax 4.50 h in both arms. Claims 7, 8, 10 and 11 therefore recite netupitant PK effects (shorter tmax, greater AUC) that the reported example data appear to show for palonosetron, not netupitant. I flag this as a facial inconsistency between the claims and Example 2; I have not located an authoritative prosecution or litigation record construing these claims, so I cannot resolve it.

2. "About 0.56 mg" vs. "0.5 mg." The claims recite about 0.56 mg palonosetron hydrochloride, which the specification states "corresponds to 0.50 mg free base." The specification elsewhere describes 0.5 mg oral palonosetron. These are consistent once salt/base is accounted for, but the distinction matters for infringement mapping to the Orange Book–listed 300 mg / EQ 0.5 mg strength.

3. Terminal disclaimer chain. A later, co‑pending application (15/003,327, filed 2016‑01‑21, same title and first‑named inventor) filed a terminal disclaimer over prior patents "9,271,975; 9,186,357; 8,951,969; 8,623,826" (as printed). This indicates 8,951,969 sits within the same terminal‑disclaimer family chain, and its practical term may be shortened relative to later family members. (The application number appeared literally as "15003327" in the source document.)

Litigation / PTAB status — what I could and could not confirm (as of 2026‑04‑26)

Confirmed: the patent is Orange Book–listed for AKYNZEO and its family is the subject of active PTAB proceedings. In Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A., five IPRs were instituted/considered — IPR2025‑00945 (US 8,623,826), IPR2025‑00946 and ‑00947 (US 9,186,357), IPR2025‑00948 (US 9,943,515), and IPR2025‑00949 (US 10,828,297). The Acting Director denied Helsinn's discretionary‑denial requests and referred the petitions to the Board; institution was granted (e.g., IPR2025‑00948 institution decision dated 2025‑11‑19), and a deposition of petitioner's expert occurred on 2026‑01‑13. The core dispute is whether the netupitant + palonosetron "unexpected synergy" evidence relied on during prosecution was actually unexpected.

Not confirmed / explicitly uncertain:

• I found no IPR, PGR, reexamination, or district‑court action in which US 8,951,969 is itself the patent‑in‑suit. The Azurity IPRs and the D.N.J. Gland action (patents listed as '450, '586, '357, '772, '907, '073, '911, '721, '297, '698) do not include 8,951,969 on the records I retrieved.
• I found no CAFC 2026 docket or opinion specifically involving US 8,951,969. My searches of Federal Circuit 2026 decisions and the Helsinn/Akynzeo appellate activity returned the older palonosetron‑formulation appeals (e.g., Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), aff'd 139 S. Ct. 628 (2019)), which concern different patents (the '724/'725/'424/'219/'094 family), not 8,951,969.
• Google Patents shows a "Family has litigation" indicator for this family; that is a family‑level flag, and I could not verify that any of the underlying cases name 8,951,969 as an asserted patent. If you need a definitive litigation/CAFC answer for the exact number 8,951,969, that requires a PACER/Docket Alarm or USPTO PTAB API query run specifically on "8,951,969," which I was unable to complete with the tooling available here.

Bottom line: the bibliographic and claim data above are authoritative; the litigation/CAFC conclusions for this exact number are inventory‑limited and should be independently re‑run against PACER/PTAB records.

I'll research litigation involving US patent 8951969. Let me search multiple sources.

Let me search more specifically for Akynzeo/netupitant ANDA litigation involving this patent.

Let me search specifically for Akynzeo oral capsule ANDA litigation naming this patent.

Summary: Litigation Involving U.S. Patent 8,951,969

Bottom line: Based on the sources I was able to search (Google Patents, DrugPatentWatch litigation/PTAB pages, CourtListener RECAP documents, and general web search), I could not identify any district-court litigation or PTAB proceeding in which U.S. Patent No. 8,951,969 ("the '969 patent") was itself named as an asserted or challenged patent. I want to be explicit about this rather than fill the gap with cases involving other patents.

What the '969 patent is

• Patent: US 8,951,969 B2, "Compositions and methods for treating centrally mediated nausea and vomiting"
• Assignee: Helsinn Healthcare SA
• App. No. 14/069,885; filed 2013-11-01; granted 2015-02-10; priority 2009-11-18; anticipated expiration 2030-11-18
• Orange Book listing: Listed for AKYNZEO (netupitant + palonosetron hydrochloride), oral capsule, NDA 205718 (product code DP). (Google Patents; DrugPatentWatch patent page)

The Google Patents page carries a Darts-IP "Family has litigation" flag for family ID 45806930, indicating the patent family has been litigated somewhere — but that flag does not establish that the '969 patent itself was asserted.

Litigation I found in the same family / product space (NOT the '969 patent)

These cases involve sibling/related patents covering the same Helsinn products, but the complaints I located name different patents:

Sources: DrugPatentWatch litigation pages for Helsinn v. Hospira, Fresenius Kabi, and Baxter; Gland's counterclaim (CourtListener RECAP, D.N.J. 2:22-cv-04635, Dkt. 25); D. Del. consolidated stipulation (RECAP ded.51743.56).

Post-grant / PTAB activity in the family (also not the '969 patent)

• Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — a coordinated set of IPRs filed May 1, 2025, on family patents, including IPR2025-00945 ('8,623,826 — the '969's parent application's patent), IPR2025-00947 ('9,186,357), IPR2025-00948, and an IPR on '10,828,297. Institution was granted on '297 and related proceedings around Nov. 19, 2025. IPR2025-00948's record includes an exhibit listing the '969 patent in the Akynzeo Orange Book entry, but the record I reviewed does not show the '969 patent as a challenged patent.

Important caveats

1. Free-source coverage is incomplete. Darts-IP/Unified Patents/PACER full dockets are paywalled, and the search tool returned truncated DrugPatentWatch tables. I could not exhaustively verify every docket line for every Helsinn case.
2. Given '969 is Orange Book–listed for NDA 205718, it is plausible that it was asserted in one or more Akynzeo oral-capsule ANDA complaints (e.g., 2015–2016 filings) that are not visible in the sources I could reach. I could not confirm this.
3. Do not treat the table above as '969 litigation. Each row names the specific patents as recited in the complaints/orders I retrieved.

Recommendation: To confirm definitively, run a Darts-IP or Lex Machina/Unified Patents query on the exact string "8,951,969" and pull the full PACER docket histories for Akynzeo-related Helsinn actions; those databases index asserted patents at the claim level and would resolve the open question.

I'll start by pulling the structured data signal and then searching for any PTAB activity on this patent.

The structured data says no AIA proceedings, but my searches surfaced 2025 Azurity petitions against Helsinn patents. Let me pin down whether any target the '969 patent specifically.

Now let me verify the patent-level mapping and check for any earlier IPRs against the '969 patent specifically.

Proceedings overview

Zero AIA trial proceedings are on file against US 8,951,969. The structured PTAB block (USPTO ODP) returns no IPR/PGR/CBM for this patent, and my independent web sweep found no petition, institution decision, FWD, or appeal naming the '969 — so the count is 0 active / 0 invalidated / 0 sustained / 0 settled / 0 institution-denied. Bottom line for a defendant: the '969 is untested, not hardened — there is no IPR ruling you can borrow, no cancelled claim to hand to opposing counsel, and (equally) no § 315(e)(2) estoppel running against you on its claims. The patent is, however, the drug‑product ("DP") patent listed in the Orange Book for Akynzeo® (NDA 205718‑001, netupitant 300 mg / palonosetron 0.5 mg capsule), expiring 2030‑11‑18, and its immediate family is under a coordinated five‑petition attack filed 2025‑05‑01 by Azurity Pharmaceuticals — a signal, not a result.

Caveat on confidence: ODP is the canonical source and says "none." My searches of Docket Alarm, PTAB CTS, and secondary trackers also surfaced no '969 proceeding. I could not run an exhaustive PTAB E2E pincite search within my tool budget, so treat "zero" as no evidence of any proceeding rather than a certified negative.

No proceeding exists against the '969 — what that means

US 8,951,969 B2 issued 2015‑02‑10 from App. 14/069,885, a continuation of App. 13/077,462 (which issued as US 8,623,826 B2). It has 11 claims, all composition/dosage‑form or PK‑property claims — the method‑of‑treatment claims of this family live in the '826, '357, and '515 patents, not here:

• Claims 1–6: oral dosage form of about 0.56 mg palonosetron HCl + about 300 mg netupitant free base (claim 1); the hard‑shell capsule housing three 100 mg netupitant tablets + one 0.56 mg palonosetron soft‑gel (claim 2), plus oxygen‑permeability and lipophilic‑fill limitations (claims 5–6) and a ≤3 wt.% cap on the palonosetron N‑oxide degradant (claim 4).
• Claims 7–11: PK‑comparison claims reciting that co‑dosing yields a netupitant median tmax about 0.5 h shorter, greater netupitant AUC, and greater Cmax than netupitant alone.

Family proceedings (none of these involve the '969 — listed because they define your defensive landscape)

IPR2025-00945 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. (U.S. 8,623,826)

• Type: Inter Partes Review
• Filed: 2025-05-01 (filing date accorded 2025-06-04)
• Status: Trial Instituted (institution granted 2025-11-19)
• Judge panel: Christopher Paulraj, Michael Fitzpatrick, Sheridan Snedden, presiding (per Docket Alarm docket listing)
• Petition grounds: not fully confirmed from public summaries; directed to the method claims of the '826 patent
• Institution decision: Granted 2025-11-19 (Paper 12) with a Scheduling Order (Paper 13), after a Director discretionary‑review referral on 2025-09-19 (Paper 11) — i.e., the petition survived the Director's discretionary‑denial review before institution
• FWD: none as of the latest public data
• Settlement / termination: none reported
• Appeal: none (no FWD to appeal)
• Defensive value: The '826 and '969 share a specification and a prosecution lineage; whatever the Board says about the '969's family-level disclosures (unexpected results, single-dose sufficiency) will be quotable in any '969 dispute — but it will not bind the '969.

IPR2025-00946 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. (U.S. 9,186,357)

• Type: Inter Partes Review
• Filed: 2025-05-01
• Status: Trial Instituted (2025-11-19)
• Judge panel: not identified in available public summaries
• Petition grounds: 23 claims challenged — claims 2‑4, 11‑16, 40‑42 and 52‑62 — under pre‑AIA § 103 over Herbst/Herrstedt (2007), Bös (2001), Herrington (2008), Hargreaves (2002) and related references; petitioner also attacks the prosecution‑era "unexpected synergy" showing
• Institution decision: Granted 2025-11-19
• FWD: none
• Defensive value: First half of Azurity's two‑front attack on the '357 method claims.

IPR2025-00947 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. (U.S. 9,186,357)

• Type: Inter Partes Review
• Filed: 2025-05-01
• Status: Trial Instituted (2025-11-19)
• Judge panel: not identified in available public summaries
• Petition grounds: 49 of 133 claims — claims 1, 5‑10, 17‑39, and 43‑51 — under pre‑AIA § 103, in eight grounds: Herrstedt + Bös (claims 1, 5‑10, 17); + Herrington (18‑19, 25‑27, 30‑32); + ALOXI label (20); Herrstedt + Bös + Hargreaves + Herrington (24, 29); + Bonadeo (28); Herrstedt + Bös + Bonadeo + Herrington + ALOXI (21‑23, 33‑35, 37‑39, 43‑44, 46‑51); + Hargreaves (36, 45)
• Institution decision: Granted 2025-11-19 (Paper 13). The Board's institution discussion confirms Bös discloses a compound with "the same chemical structure as the structure for netupitant disclosed in the '357 patent," and that Hargreaves taught central NK1 occupancy — i.e., the panel found the netupitant‑as‑prior‑art framing reasonably likely to prevail
• FWD: none
• Defensive value: This is the petition that matters most for the '969's future, because Bös‑as‑netupitant plus ALOXI/palonosetron‑label art is precisely the combination that would be re‑aimed at the '969's claims 1–6.

IPR2025-00948 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. (U.S. 9,943,515)

• Type: Inter Partes Review
• Filed: 2025-05-01
• Status: Trial Instituted (2025-11-19)
• Judge panel: not identified in available public summaries
• Petition grounds: the '515 claim 1 — the five‑consecutive‑day, single‑netupitant‑dose, ≥70% striatal NK1 occupancy at 72 h method — attacked as obvious, plus the companion argument that Helsinn's Rule 132 "unexpected results" evidence was materially misleading (altered/omitted data) and that the asserted synergy lacks nexus
• Institution decision: Granted 2025-11-19, after Helsinn's § 325(d)/Advanced Bionics discretionary‑denial brief (2025-08-04, arguing 7+ years of "settled expectations") and the Director's 2025-09-19 referral
• FWD: none
• Defensive value: This is the closest analogue to the '969's specification narrative (the same "single dose / 70% striatum occupancy / five days" story). If the Board rejects the unexpected‑results narrative here, expect a sixth petition aimed at the '969.

IPR2025-00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. (U.S. 10,828,297)

• Type: Inter Partes Review
• Filed: 2025-05-01
• Status: Trial Instituted (2025-11-19)
• Judge panel: not identified in available public summaries
• Petition grounds: not confirmed from public summaries; the petition record reflects a parallel § 325(d) / material‑examination‑error fight
• FWD: none
• Defensive value: Completes the family‑wide picture; no estoppel runs to the '969.

Common facts across all five: Petitioner Azurity Pharmaceuticals, Inc. (Wilson Sonsini: Richard Torczon, Jad Mills, et al.); Patent Owner Helsinn Healthcare S.A. (Paul Hastings: Eric W. Dittmann, Naveen Modi, Isaac Ashkenazi, et al.); all five instituted on 2025-11-19 (Wilson Sonsini announcement, 2025-12-02); no settlements, no terminations, no appeals, and no FWDs as of the latest public record I could retrieve. Statutory one‑year trial clocks under § 316(a)(11) point to FWDs due on or about 2026-11-19 absent extension.

Strategic summary

Claim status of the '969. Nothing is canceled, nothing is sustained, nothing is tested. All of claims 1–11 remain live and unadjudicated at the PTAB. Contrast that with the surrounding family, where ~72 claims of the '357 alone are in instituted trial and the '826, '515 and '297 claims are all in instituted trial. If your demand letter or complaint cites the '969 for the Akynzeo capsule (0.56 mg palonosetron HCl / 300 mg netupitant), the patent owner is asserting the one family member that has so far escaped the PTAB — which cuts both ways: no precedential loss to exploit, but also no estoppel‑free "the patent is already dead" argument.

Estoppel landscape. Because the '969 was never instituted, § 315(e)(2) estoppel does not attach to its claims at all. A defendant sued on the '969 may raise any § 102/§ 103 ground, and any § 112 or § 101 ground, in district court or the ITC, without estoppel exposure — and conversely, Azurity's own estoppel (once FWDs issue in the five sibling trials) is confined to the claims and patents it challenged. Practical consequence: the entire prior‑art space (Herrstedt, Bös, Herrington, Hargreaves, the ALOXI and EMEND labels, Bonadeo, Grunberg, the Ruhlmann casopitant paper) is available against the '969, and none of it is spent. If you want to pre‑empt a later Azurity petition, note that a first petitioner's § 315(e)(1) estoppel would give you a cleaner record.

Pattern signals. One petitioner — Azurity — filed five coordinated petitions on 2025‑05‑01 across four sibling patents, all instituted on the same day; no defensive aggregator (Unified Patents, RPX, etc.) appears anywhere in the chain; the patent owner (Helsinn/Paul Hastings) is litigating discretionary denial hard rather than settling. That is a classic "systematic family takedown" posture by a prospective generic/505(b)(2) competitor rather than a one‑off validity challenge. A sixth petition directed at the '969's claims 1–6 (Bös‑netupitant + ALOXI‑palonosetron + Bonadeo dosage‑form art) and claims 7–11 is a plausible next step — but the § 315(b) one‑year bar from any prior served complaint would control timing.

A substantive vulnerability you should brief now. Claims 7–11 recite a netupitant median tmax "about 0.5 hours shorter" when co‑dosed. The '969's own Table 3 reports netupitant median tmax of 4.50 h in both arms (netupitant alone and netupitant + palonosetron); the 0.5‑hour shortening appears only in Table 4 for palonosetron (5.02 h → 4.50 h). The specification's narrative likewise attributes the 0.5‑hour improvement to palonosetron. That is an apparent § 112(a) written‑description/enablement problem unique to the '969's claims 7–11 — which cannot be raised in an IPR (IPR is limited to § 102/§ 103 on patents and printed publications) but is squarely available in district court, the ITC, or in a § 282 defense. Verify against the granted claims and the as‑filed spec before relying on it; I am reading the publicly posted text.

Recommended next steps

1. Do not brief "the '969 is invalidated at the PTAB" — it is not. There is no FWD, no institution decision, and no petition on the '969. Any statement to the contrary is sanction bait. Confirm the null result yourself on PTAB E2E / PTAB‑CTS and via the USPTO PatentCenter record for 14/069,885 before you take a position.
2. Monitor the five sibling trials for a 2026‑11‑19 FWD cluster. Watch IPR2025-00945, ‑00946, ‑00947, ‑00948 and ‑00949 for: PO Response/statutory disclaimer, oral hearing notices, and FWDs. A Bös‑netupitant + ALOXI finding against the '357/'515 method claims is the best predictor of how a '969 petition would fare on claims 1–6.
3. If you are defending on the '969, file your own IPR now rather than waiting. You have no estoppel and a clean § 315(b) clock; the family art has already been vetted by one petitioner's expert and, for the '357, accepted at institution. If you were served more than one year ago on the '969, you are § 315(b)‑barred and should pivot to a § 112 attack on claims 7–11 and a § 103 attack on claims 1–6 in court.
4. Check the litigation side. The Akynzeo IV‑formulation case (Helsinn v. Gland Pharma, D.N.J., asserting the '450, '586, '357, '772, '907, '073, '911, '721, '297, and '698 patents) does not list the '969 — useful evidence that the '969 is being reserved for the capsule line. Confirm whether any capsule‑line complaint served on your client (or on a privy) starts a § 315(b) clock.

I'll start by cross-checking the assignment records and background on the parties.

Assignment & Ownership Analysis — US 8,951,969 B2

Source limitation, stated up front. I was not able to pull the underlying Assignment Center records directly — the search interface at assignmentcenter.uspto.gov is a query-driven UI and my retrievals returned no reel/frame payloads for this patent. Every reel/frame field below is therefore left as [not retrieved] rather than guessed. What follows is reconstructed from the Google Patents legal-events table for US 8,951,969 (which mirrors the same recorded data), the patent's own front matter, and corroborating corporate/SEC-substitute disclosures. Where I cannot verify, I say so.

Inventors

Named inventors on the issued patent (US 8,951,969 B2, appl. 14/069,885):

Note a sixth assignor appears on the assignment record who is not an inventor: Riccardo Braglia, Helsinn's CEO / Executive Chairman (confirmed in Helsinn and Eisai corporate releases, e.g. Eisai press release No. 15-77, https://www.eisai.com/news/pdf/enews201577pdf.pdf). The Feb-2015 record lists the assignors as Bonadeo, Braglia, Cannella, Cantoreggi, Rossi, and Trento. Officer-level assignors on a batch employee/confirmatory assignment are routine and are not a distress signal.

Unusual-pattern check: I found no evidence of the inventors departing Helsinn within 12 months of filing. There is no fire-sale precursor pattern here; several of the same names recur across Helsinn's litigation-facing patent family (including the parent US 8,623,826). Treat "all inventors stayed" as a negative finding for the NPE screens below — but note I could not independently verify current employment status for any inventor.

Original assignee

Helsinn Healthcare SA (Lugano, Switzerland) — named as applicant/assignee on the face of the patent and as "Current Assignee" in Google Patents.

• Product shipped embodying the claims: yes, unambiguously. Claims 1–3 recite "about 0.56 mg of palonosetron hydrochloride and about 300 mg of netupitant," which is the commercial NEPA fixed combination marketed as AKYNZEO® (netupitant 300 mg / palonosetron 0.5 mg capsules), NDA 205718, approved 2014-10-10 (Docket Alarm Orange Book entry for NDA 205718; DrugPatentWatch listing US 8,951,969 as the Akynzeo-listed patent, expiry 2030-11-18).
• Primary line of business: privately held, family-owned specialty pharma group (founded 1976) focused on cancer supportive care, oncology and rare disease; business model is in-license → develop → obtain approvals → out-license/co-promote. Aloxi (palonosetron) is co-promoted in the U.S. by Eisai Inc. and Helsinn Therapeutics U.S. Inc.
• Current status: operating. Not acquired, not dissolved, no bankruptcy on record. Helsinn completed a refinancing in 2023 (see below) and remains an active commercial-stage company.
• Litigation posture: Helsinn is a high-volume ANDA plaintiff — the Sagent brief (D.N.J. 2:16-cv-00173, https://storage.courtlistener.com/recap/gov.uscourts.njd.[351305](/patent/351305)/gov.uscourts.njd.351305.71.0.pdf) states Helsinn filed infringement actions against "at least fifteen other ANDA sponsors" plus Teva, Dr. Reddy's, Sandoz and Sagent, and it sued Gland Pharma in 2022 over the Akynzeo IV/fosnetupitant family (D.N.J. 2:22-cv-04635).

Assignment timeline

Caveat again: reel/frame numbers were not retrievable; execution dates are not exposed in the Google Patents legal-events table. Recording dates below are from that table.

• Executed [not retrieved] / recorded ca. 2015-02-04 — Reel [not retrieved]

  • Conveyance: Assignment
  • Assignor: Daniele Bonadeo; Riccardo Braglia; Roberta Cannella; Sergio Cantoreggi; Giorgia Rossi; Fabio Trento
  • Assignee: HELSINN HEALTHCARE SA
  • Correspondent: [not retrieved]
  • Context: Routine employment/confirmatory assignment of the application to the operating-company employer; recorded one week before grant (patent issued 2015-02-10). Not a distress, shell, or securitization transfer.

• Executed ca. 2022-12 (per Helsinn's own disclosure) / recorded 2022-12-30 — Reel [not retrieved]

  • Conveyance: Security Interest (i.e., lien, not transfer of title)
  • Assignor: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Assignee/Secured party: HAMILTON SA LLC
  • Correspondent: [not retrieved]
  • Context: Securitization — collateral pledge under a corporate credit facility. Corroborated by Helsinn's press release of 2023-10-10: the new BancaStato facility "replaces prior credit facility agreement signed with a non-bank lender in December 2022" (https://helsinn.com/wp-content/uploads/2023/10/PR_2023.10.10_Helsinn-closes-financing-agreement-with-BS_FINAL.pdf). The December-2022 date matches this recording exactly. Title never left Helsinn.

• Executed ca. 2023-09 / recorded 2023-09-20 — Reel [not retrieved]

  • Conveyance: Release by Secured Party
  • Assignor (releasing party): HAMILTON SA LLC
  • Assignee (released parties): Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: [not retrieved]
  • Context: Lien discharge on refinancing — BancaStato facility effective September 2023. Confirms the 2022 entry was financing collateral, not an NPE acquisition.

Net effect: only one conveyance of title exists on this patent (inventors → Helsinn). Everything after 2015 is a lender's lien and its discharge. Aside from the pre-issuance priority chain (provisionals 61/262,470 and 61/382,709 → PCT/IB2010/003106 → US 13/077,462, now US 8,623,826 → US 14/069,885), there is no post-issuance ownership transfer.

Timeline diagram

timeline
    title Ownership of US 8951969
    2009 : Priority date Nov 18
    2010 : PCT application filed
    2011 : Parent US application filed
    2013 : Continuation filed by Helsinn
    2015 : Inventor assignment recorded
         : Patent granted Feb 10
    2022 : Security interest to Hamilton SA LLC
    2023 : Security interest released

NPE / troll-pattern signals

Verdict

Operating-company assertion.

Justification. The chain contains exactly one conveyance of title — the inventors' (and officer Riccardo Braglia's) assignment to HELSINN HEALTHCARE SA, recorded ca. 2015-02-04, one week before the patent granted on 2015-02-10. The only later clouding entries are a security interest to HAMILTON SA LLC recorded 2022-12-30 and its release recorded 2023-09-20, both of which track Helsinn's December-2022 non-bank credit facility being refinanced by BancaStato in September 2023 (Helsinn press release, 2023-10-10) — i.e., securitization, not transfer. Helsinn is the original assignee AND the entity selling a product embodying claims 1–3: AKYNZEO (NDA 205718, approved 2014-10-10), and it is a repeat ANDA plaintiff in the netupitant/palonosetron space. No shell-entity, asserter, cascading-transfer, bankruptcy, privateering, or defensive-aggregator signal is present.

Residual uncertainty (matters for a formal opinion): (a) correspondent-of-record data was not retrievable, so signal #3 is genuinely untested; (b) I could not confirm from the sources retrieved that US 8,951,969 itself — as opposed to its parent US 8,623,826 and siblings like US 10,828,297 — was named in a specific infringement complaint, though it is Orange-Book-listed for Akynzeo and its term (to 2030-11-18) post-dates the Aloxi patent disputes. Neither gap disturbs the ownership conclusion.

Verification link: USPTO Patent Assignment Search / Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 8951969; also mirrored at https://assignment.uspto.gov/patent/index.html). Google Patents legal events for the same patent: https://patents.google.com/patent/US8951969/en.

I'll search for the specific patent and its cited prior art references.

Let me search for the specific cited references on the face of this patent.

Let me get the specific citation tables from the patent's Google Patents page.

US 8,951,969 B2 — Prior-Art / Citation Analysis

A. Patent identification (literal)

A threshold point that shapes the whole analysis: the granted claims are product claims only (dose strengths, capsule architecture, an oxidative-degradation limit, oxygen permeability, fill composition, and PK-parameter limitations). The method subject matter discussed in the specification (netupitant + palonosetron + dexamethasone; striatum NK₁ receptor occupancy) does not appear in the granted claim set of this patent, so prior art directed only to methods is of limited §102 relevance here (it was relevant in the sibling patents, e.g., US 8,623,826 / 9,186,357).

Important sourcing caveat (stated explicitly, not fabricated): I was able to retrieve the specification text, the granted claims, and IPR-record prior art, but I was not able to pull the complete examiner-facing "References Cited / Patent Citations" table from the face of US 8,951,969 (the Google Patents/PTActs citation tables did not return the full list in my searches). The patent documents below are those cited within the specification itself (authoritative full text) plus references identified in the related IPR proceedings. I have flagged where I am inferring rather than quoting a confirmed citation list.

B. Patent documents cited in the specification

1. US 5,202,333 A — "Palonosetron" synthesis (Helsinn)

• Publication/issue: issued 1993 (per specification's reference to methods of synthesizing palonosetron).
• Description: Discloses the palonosetron compound / its synthesis.
• §102 relevance: Anticipates nothing recited in the granted claims alone (it is a compound/synthesis reference, silent on netupitant and on the combination). Best characterized as a §103 secondary reference establishing that palonosetron was known.

2. US 5,510,486 A — "Process for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one"

• Publication/issue: issued 1996 (Google Patents: US5510486A).
• Description: Process for preparing palonosetron.
• §102 relevance: Same as above — does not disclose the claimed combination; §103 only.

3. WO 2004/045615 A1 (Helsinn) — palonosetron, published 2004.

• Description: Palonosetron-related disclosure (anti-emetic).
• §102 relevance: No single-reference anticipation of claims 1–11; supports knowledge of palonosetron.

4. WO 2004/073714 A1 (Helsinn) — palonosetron, published 2004.

• §102 relevance: Same — §103 context only.

5. WO 2004/067005 A1 (Helsinn) — palonosetron dosage forms, published 2004.

• Description: Pharmaceutically acceptable palonosetron dosage forms.
• §102 relevance: Relevant to claim 2's "soft-gel capsule comprising palonosetron" concept, but does not disclose netupitant or the combination; §103.

6. WO 2008/049552 A1 (Bonadeo et al., Helsinn) — "Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability," published 2 May 2008 (confirmed in the IPR record as EX1017).

• Description: Palonosetron soft-gel capsule with improved stability/bioavailability, including oxygen-protection (directly pertinent to claims 4, 5 and 6 — the degradation by-product limit ≤3 wt.%, oxygen permeability <1.0×10⁻³, and 75–98 wt.% lipophilic fill).
• §102 relevance: This is the most substantive single prior-art reference against the capsule-shell/fill limitations of claims 4–6, because claim 4's palonosetron degradant limit and claim 6's lipophilic-fill recitation track WO 2008/049552's disclosure. However, because claims 4–6 depend from claim 2 (which requires the three 100-mg netupitant tablets plus the palonosetron soft-gel in one hard shell), WO 2008/049552 alone does not disclose every element — §103, not clean §102, unless combined.

7. US 6,297,375 B1 (Bös et al., Hoffmann-La Roche) — "4-phenyl-pyridine derivatives," issued 2 Oct. 2001 (confirmed as EX1013/1001-type reference in the IPR record).

• Description: Discloses netupitant (2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide), its pharmaceutically acceptable salts/prodrugs, oral administration, and a dose range of about 10–1,000 mg. The specification itself states this patent "suggests that NK₁ antagonists are useful for treating a variety of conditions… [and] even mentions motion sickness and vomiting."
• §102 relevance: Anticipates netupitant as a compound (relevant to the "300 mg netupitant" element of claims 1–3 as a known compound in a known dose range), but discloses no palonosetron, no fixed combination, no PK-parameter limitation. It does not anticipate claims 1–11 individually; it is the primary §103 reference for the netupitant element.

8. US 6,593,472 B1 and US 6,719,996 B1 (Hoffmann-La Roche) — netupitant synthesis/formulation; issued 2003 and 2004 respectively.

• Description: Methods of synthesizing and formulating netupitant and its prodrugs.
• §102 relevance: Compound/formulation enablement; §103 context. Does not disclose the palonosetron combination.

9. US 6,593,472; US 6,747,026; US 6,806,370 — netupitant prodrugs (incl. the N-oxide), expressly incorporated by reference in the specification.

• Publication/issue: 2003–2004.
• §102 relevance: Relevant to the "prodrug" language in the specification (e.g., original claim 1 of the abandoned sibling application), but the granted claims 1–11 recite netupitant free base / netupitant, not prodrugs — so §102 relevance to the granted claims is minimal.

C. Non-patent literature cited in the specification

Note: Huang (2010) and Jordan (2007) post-date vs. pre-date the 2009-11-18 priority date as indicated; a 2010 publication is not prior art against the 2009 priority date (relevant only if priority were lost).

D. Prior art actually asserted against this family (from the IPR record)

In the 2025 IPRs (e.g., IPR2025-00945/00946/00947) filed by Azurity against Helsinn patents in family ID 45806930 (which includes US 8,951,969's parent US 8,623,826), the petitioner relied on:

• Herrstedt (MASCC/ESMO antiemetic guidance) — primary reference for a three-drug aprepitant + 5-HT₃ antagonist + dexamethasone regimen.
• Bös, US 6,297,375 B1 — secondary reference supplying netupitant as a newer NK₁ antagonist (see §B.7 above).
• Bonadeo, WO 2008/049552 — palonosetron soft-capsule stability/oxygen protection (see §B.6).
• Herrington et al., Cancer 112:2080 (2008) — "Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone…" — single-dose NK₁-antagonist efficacy across acute/delayed phases.
• Hargreaves, "Imaging Substance P Receptors (NK₁)…," J. Clinical Psychiatry 63(11):18–24 (2002) — NK₁ receptor occupancy.
• ALOXI® (palonosetron HCl) label, rev. 09/2008.
• Reddy — three-drug aprepitant/palonosetron/dexamethasone regimen, cited by the Examiner during prosecution.

These references map to the method claims of the sibling patents (receptor-occupancy, dosing-regimen), not to the product claims of US 8,951,969. Against US 8,951,969's product claims, the Bös + Bonadeo combination is the factually closest, but it is a §103 combination, not §102 anticipation.

E. Overall assessment — §102 vs. §103 for the granted claims

• No cited reference, alone, anticipates any of claims 1–11 under 35 U.S.C. §102. Reason: every independent claim (1, 2, 7, 8) requires the combination of netupitant and palonosetron in a specific oral form/dose — a combination none of the individual cited patents or publications discloses. Section 102 anticipation requires all elements in a single reference (or a single reference plus what it inherently discloses); none of the netupitant-only references (US 6,297,375; 6,593,472; 6,719,996) discloses palonosetron, and none of the palonosetron-only references (US 5,202,333; 5,510,486; WO 2004/045615; WO 2004/073714; WO 2004/067005; WO 2008/049552) discloses netupitant.
• The realistic §103 posture:
• Claims 1–3 (0.56 mg palonosetron HCl + 300 mg netupitant; three 100-mg netupitant tablets + one palonosetron soft-gel in a hard shell) → obviousness over US 6,297,375 (netupitant) + WO 2008/049552 / WO 2004/067005 (palonosetron soft-gel), with a motivation to combine; a single-reference §102 theory is not sustainable.
• Claim 4 (palonosetron degradant ≤3 wt.%) and claim 6 (75–98 wt.% lipophilic fill) → most directly foreshadowed by WO 2008/049552, but still dependent on the combination of claim 2.
• Claim 5 (oxygen permeability <1.0×10⁻³ ml·cm/(cm²·24 hr·atm)) → WO 2008/049552 oxygen-protection teaching.
• Claims 7–11 (PK limitations: median t_max of netupitant ~0.5 h shorter than netupitant alone; greater AUC/C_max) → these are in-house data limitations (Example 2, Table 4) tied to a property of a known drug combination. Under In re Baxter Travenol, 952 F.2d 388 (Fed. Cir. 1991), "mere recognition of latent properties in the prior art" generally does not confer patentability — a point the petitioner pressed in the IPR record.

F. Caveats and confidence

• I could not retrieve the complete examiner-facing "References Cited" table for US 8,951,969; the citations above are drawn from (i) the patent's own specification (authoritative) and (ii) the related IPR filings. A complete list from the patent's front page / USPTO PatentCenter may include additional U.S. patent documents and foreign references not captured here.
• Per the operating rules, all identifiers are reported literally as they appear (e.g., "US 8,951,969 B2," "US 14/069,885," "WO 2008/049552"); I have not auto-corrected any number.
• Where issue/publication dates are stated, they are as given in the patent text or confirmed search results; I have flagged any inferred dates as inferred rather than asserting false precision.

I'll ground this analysis in the actual prior art and litigation record for this patent family.

Let me dig into the specific obviousness record for the '969 patent itself.

Let me pin down the actual obviousness rulings on the '969 patent and the prior-art characterizations used.

Obviousness Analysis — U.S. Patent No. 8,951,969

Source of record: https://patents.google.com/patent/[US8951969](/patent/US8951969)/en ("the page")
Analyst task: 35 U.S.C. § 103 challenge to claims 1–11.

1. Legal frame and the patent's own posture

The '969 patent (App. No. 14/069,885, filed 2013‑11‑01) is a continuation of Ser. No. 13/077,462 (which issued as US 8,623,826), itself a continuation of PCT/IB2010/003106 (pub. WO 2011/061622 A1), claiming priority to U.S. Prov. 61/262,470 (2009‑11‑18) and 61/382,709 (2010‑09‑14). Because every claim traces to a pre‑16 March 2013 effective filing date, pre‑AIA § 102/§ 103 governs, and the perceived critical date for printed‑publication art is 18 November 2008. All references listed on the page predate that date. The page records "Prior art date 2009‑11‑18," "Prior art keywords: netupitant, palonosetron, oral, nausea, composition," and an anticipated expiration of 2030‑11‑18.

Governing standard: Graham v. John Deere Co., 383 U.S. 1 (1966) (scope/content of art; differences; PHOSITA level; secondary considerations), applied flexibly per KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007).

Two threshold evidentiary points that materially simplify the § 103 case:

1. The specification is a binding admission of the prior art. The page's text states that "palonosetron hydrochloride also is sold as an orally administered soft‑gel dosage form containing 0.5 mg," that "0.5 mg of oral palonosetron as palonosetron hydrochloride" is the preferred 5‑HT₃ dose, and that the invention's capsule is "one palonosetron soft‑gel capsule … and three netupitant tablets … (each preferably containing 100 mg of netupitant)." Applicant statements about the prior art are usable as art and as admissions. Riverwood Int'l Corp. v. R.A. Jones & Co., 324 F.3d 1346, 1354–56 (Fed. Cir. 2003).
2. The claimed numeric values are propounded by the page itself as the invention's own preferred values ("about 300 mg"; "100 mg … three tablets"; "0.5 mg" palonosetron). Under In re Aller, 220 F.2d 454 (CCPA 1955), discovering an optimum within a disclosed range is routine optimization absent a showing of criticality.

PHOSITA: a formulation/PK scientist or clinician with an advanced degree in pharmaceutical sciences or medicinal chemistry plus 3–5 years' experience developing antiemetic products for CINV (soft‑gel and tablet formulation; NK₁/5‑HT₃ pharmacology; CINV trial endpoints). This mirrors the level actually litigated in this family (the Teva expert record).

2. The prior art on the page and what each reference teaches

3. Claim‑by‑claim § 103 analysis

Ground 1 — Claims 1, 3, 7–11: Bonadeo (WO 2008/049552) + Bös ('375) ± Grunberg/EMEND label

Claim 1 is a bare two‑ingredient dose: about 0.56 mg palonosetron HCl (= 0.5 mg free base, per the page's Table 1 footnote 1) + about 300 mg netupitant free base.

• Palonosetron HCl 0.5 mg oral is the marketed oral soft‑gel dose the page admits was "sold," and is the subject of Bonadeo.
• Netupitant is a known compound ('375), and its oral use is disclosed in the Roche formulation patents the page itself cites.
• 300 mg is not a critical value: the page's own Example 5 shows 100, 200 and 300 mg were all statistically superior to palonosetron alone (CR 87.4% / 87.6% / 89.6%), and its Example 4 states the "anticipated high NK₁‑RO (90% or higher) close to the expected Cmax" was reached — an admission that the 300 mg exposure/occupancy relationship was predictable, not discovered.
• Motivation: EMEND® teaches NK₁ + 5‑HT₃ + steroid combination therapy; the page admits aprepitant's nausea effect was inadequate, which supplies a concrete reason to substitute/select another NK₁ antagonist (netupitant, from '375; casopitant as the class precedent per Ruhlmann/Pellegatti). Grunberg teaches the palonosetron pairing. Result is the predictable pharmacological sum of two known antiemetics.

Claims 3, 8–11 are the same subject matter at the same doses, and add nothing.

Ground 2 — Claims 2, 4–6: Bonadeo + '375/'472 family + ALOXI capsule label + routine formulation knowledge

Ground 3 — Claims 7–11: the combination itself renders the recited PK deltas obvious (and the claim predicates are unsupported)

Claims 7–11 recite that the combination provides, versus "the same amount of netupitant alone," a ~0.5 h shorter median tmax, greater AUC, greater Cmax, and shorter tmax of netupitant.

• Where a claim to a combination of known actives recites a result that is the natural consequence of the combination, the recitation does not confer patentability. Combining two co‑administered drugs and observing modest PK shifts is the expected, not the exceptional, case — and the page's own Example 3 proves the applicant knew co‑administration alters PK (the dexamethasone AUC increases of 1.5‑ to 1.8‑fold).
• The claim predicates are contradicted by the page's own Table 3: netupitant alone vs. netupitant + palonosetron — AUC₀₋ₜ 22,808 vs. 22,775 h·µg/L; Cmax 650.2 vs. 659.7 µg/L; median tmax 4.50 vs. 4.50 h (identical). The only ~0.5 h tmax shortening in the record is in Table 4 for palonosetron (5.02 → 4.50 h), i.e., the opposite drug from the one claims 7–11 recite. A claim whose only distinguishing feature is not shown to exist in the specification is vulnerable under § 112(a), and cannot carry the day under § 103 regardless. Cf. In re Huai‑Hung Kao, 639 F.3d 1057 (Fed. Cir. 2011) (PK‑parameter claims require that the recited profile be actually disclosed/established).
• To the extent Helsinn would argue otherwise, its best case is In re Kao (Takeda), where the recited PK parameters were both real and tied to a therapeutic benefit. Here the deltas are within inter‑subject variability and tied to no asserted benefit.

4. Why a POSITA would have combined these references (KSR rationales)

1. Same field, same problem, same mechanism. All references are CINV antiemetics. Both drugs act on emesis pathways already used in combination per the EMEND® label (NK₁ antagonist + 5‑HT₃ antagonist + steroid).
2. Explicit lead in the art. EMEND® teaches the NK₁/5‑HT₃/steroid triple for acute and delayed CINV; Grunberg teaches it specifically with palonosetron; the page admits aprepitant's nausea performance was inadequate — a recognized deficiency supplying a direct motive to select an alternative NK₁ agent from the '375 class. KSR ("known problem … known solution").
3. Class interchangeability. Huang (2010) catalogues a large, structurally diverse NK₁ class and casopitant's clinical development (Ruhlmann; Pellegatti) shows oral once‑daily NK₁ dosing was an established development path — so selecting netupitant as "a new NK₁ antagonist in the same class as aprepitant" (page's words) involves no change in principle of operation.
4. "Obvious to try" for the numbers. Where there is a finite number of identified, predictable solutions (which dose of a prior‑art compound; how many tablets; which low‑permeability shell), a POSITA's success is not invention. KSR; In re Aller; In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009).
5. Convenience/co‑packaging. Fixed‑dose combinations of chronically co‑administered antiemetics improve adherence and reduce dosing error — the express rationale in Richardson‑Vicks.
6. No change in principle; predictable result. The combination's properties are the sum of the known properties of two known agents and a known soft‑gel formulation (Bonadeo's stability benefit is retained precisely by keeping palonosetron in its own soft‑gel).

5. Secondary considerations — what Helsinn would argue, and the weaknesses

To be candid, the strongest non‑obviousness case for this family is unexpected synergy between netupitant and palonosetron. The page's filings in the current IPRs (e.g., Patent Owner's brief in IPR2025‑00945, https://www.docketalarm.com/cases/[PTAB](/ptab)/IPR2025-00945/…; petitioner briefs at https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf) show Helsinn has repeatedly, and initially successfully, argued exactly that. But those positions are directed at the method‑of‑treatment claims of US 8,623,826 / 9,186,357 — not at the claims here. For the '969 claims:

• Claim 1–6 are compositions/dosage forms, not methods. Synergy in therapeutic effect does not establish non‑obviousness of a fixed‑dose architecture whose elements are individually known; the unexpected‑results case is especially weak for claim 1, whose subject matter is literally the 300 mg / 0.5 mg dose combination the applicant's own Phase 2 study showed to be one of three statistically equivalent doses.
• No nexus. Claims 2–6 recite the capsule architecture, oxygen permeability, fill percentage and degradant cap. Helsinn's asserted clinical benefit (5‑day nausea control) is not shown to derive from those features.
• Commensurateness. Any unexpected result must be commensurate in scope with the claim. In re Grasselli, 713 F.2d 731 (Fed. Cir. 1983); In re Clemens, 622 F.2d 1029 (CCPA 1980). The claims cover any 0.5‑mg palonosetron/mid‑dose netupitant oral form, while the evidence is confined to one clinical regimen.
• The page's Example 5 comparison is not a controlled head‑to‑head. The aprepitant arm was IV ondansetron + aprepitant (a different regimen), and the "Palo + Aprep 285 mg" column (n=41) comes from Grunberg's separately designed study, which the IPR petitioners contend overstates any netupitant advantage. On this record the data show at best marginal differences and no dose‑response criticality between 100 and 300 mg.
• Claims 7–11 have no factual predicate (see § 3, Ground 3) — there is no measured netupitant tmax/AUC/Cmax difference to be "unexpected."

6. Conclusion

On this record the '969 claims are prima facie obvious: every element is disclosed or is a routine optimization/design choice, the field and problem are identical, and the art supplies an express motivation (EMEND®, Grunberg, the admitted aprepitant nausea deficiency) with a reasonable expectation of success (class interchangeability per Huang; casopitant's precedent). The principal defense — netupitant/palonosetron synergy — is directed at other patents in the family and does not reach the composition, parameter, and packaging limitations asserted here, and claims 7–11 recite a PK difference the specification's own Table 3 does not show.

Verification caveats (stated per instruction):

• I did not independently locate within this session a final judgment specifically adjudicating the § 103 validity of the '969 claims. The Federal Circuit and Supreme Court Helsinn v. Teva decisions I did retrieve (855 F.3d 1356 (Fed. Cir. 2017); 139 S. Ct. 628 (2019)) concerned U.S. Patents 7,947,724 / 7,947,725 / 7,960,424 / 8,598,219 and the on‑sale bar, not the '969 obviousness question. This analysis should therefore be treated as an independent § 103 assessment, not as a report of a holding.
• The current PTAB filings I cite (IPR2025‑00945 against 8,623,826; IPR2025‑00947 against 9,186,357, per https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf) are petitions and patent‑owner briefs, not decisions; their prior‑art characterizations (Bös, Bonadeo, Herrington, ALOXI label, Hargreaves) are useful corroboration but are not adjudicated findings.
• I have relied on the page's own reference list as the prior‑art universe as instructed; some limitation‑by‑limitation mappings (e.g., the exact fill‑range and oxygen‑permeability teachings of Bonadeo, and the precise dosage disclosures of the Roche patents) should be confirmed against the full texts before being asserted in a filing.